title: Predictors of high yield and purify of CD34(+) cell-selected PBPC, collected from patients with multiple myeloma.
abstract: BACKGROUND
  Wide ranges i n cell recovery and purity may be observed following CD34(+) cell selection of mobilized HPC componetns. Characteristics of the mobilized HPC, associated with isolation of a high CD34(+) cell yield and purity following cell selection, have yet to be defined.
  
  
  METHODS
  Cell number and purities were determined before and after 56 CD34(+) cell-selection procedures, performed using the CellPro Ceprate SC system from April 1997 to February 1998. HPC were collected from 28 patients with multiple myeloma, following cyclophosphamide (60mg/kg) and G-CSF (10microg/kg) mobilization.
  
  
  RESULTS
  A medium of 47.9% (range 1.5-109.6%) CD34(+) cells were recovered in the enriched (ENR) fraction. A linear correlation existed between total CD34(+) cells in the ENR fraction and total CD34(+) cells in the START fraction (R2=0.93); there was a logarithmic correlation between CD34 ENR fraction purity and START fraction purity (R2=0.73). A START CD34(+) cell purity > 0.42% improved purity in the ENR fraction. A median of one (range one to nine) procedure was required to isolate 2 x 10 6 CD34(+) cells/kg. Three patients pretreated with alkylating agents failed to mobilized adequate numbers of HPC.
  
  
  CONCLUSIONS
  Isolation of highly purified CD34(+) cell-selected components using the Ceprate SC system in dependent on the CD34(+) purity of the lekapheresis component collected. Mobilization regimens should be used to maximize CD34(+) cell purity in stem cell authografts if CD34(+) cell selection is to be performed. Similar strategies should be used to evaluate other cell-selection devices as they become available.
authors.affiliation: Cell Manipulation, Gene Transfer and Cryopreservation Laboratories, Dana-Farber Cancer Institute, Boston, USA.
authors.forename: I J
authors.initials: IJ
authors.lastname: Webb
authors.forename: R L
authors.initials: RL
authors.lastname: Scholssman
authors.forename: M
authors.initials: M
authors.lastname: Jiroutek
authors.forename: D
authors.initials: D
authors.lastname: Doss
authors.forename: C A
authors.initials: CA
authors.lastname: Cohen
authors.forename: A
authors.initials: A
authors.lastname: Freeman
authors.forename: D M
authors.initials: DM
authors.lastname: Schott
authors.forename: K C
authors.initials: KC
authors.lastname: Anderson
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000096:biosynthesis*; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D007937:Leukapheresis; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000628:therapy*; D013234:Stem Cells / Q000166:cytology; D013997:Time Factors
chemical_list: D018952:Antigens, CD34